Traditional Chinese medicine composition, traditional Chinese medicine preparation and application thereof

Through the ingredients such as ephedra, cinnamon twig, fish oil in the traditional Chinese medicine composition, combined with the principle of traditional Chinese medicine, the problem of great side effects and poor results in the treatment of cerebral infarction was solved, and the cerebral blood flow and inhibit thrombosis were improved, which significantly improved the The symptoms and pathology of cerebral infarction have preventive and therapeutic effects.

CN119033899AActive Publication Date: 2024-11-29SOUTHERN MARINE SCIENCE & ENGINEERING GUANGDONG LABORATORY (ZHANJIANG)
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411115752.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-29
Estimated Expiration
2044-08-14

AI Technical Summary

Technical Problem

Existing Western medicines have great side effects, poor results and cannot prevent cerebral infarction in the treatment of cerebral infarction. The thrombolysis treatment time window is short, and most patients cannot be delivered to the hospital in time, resulting in a high sequelae rate.

Method used

A Chinese medicine composition is proposed, including ephedra, cinnamon twig, fish oil, angelica, chuanxiong, peach kernel, Codonopsis, ginger, roasted licorice and gypsum. According to the principle of traditional Chinese medicine compatibility, it can improve hemorilysis, inhibit thrombosis and enhance Immunity, inhibition of microglia activation and neuronal damage in the brain, and preparation of cerebral infarction inhibitors.

Benefits of technology

Through multi-target effects, traditional Chinese medicine compositions improve cerebral blood flow, reduce thrombosis, enhance immunity, inhibit neuronal apoptosis, significantly improve clinical symptoms and pathological changes of cerebral infarction, and have minor toxic side effects, suitable for prevention and treatment. Cerebral infarction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033899A_ABST
    Figure CN119033899A_ABST
Patent Text Reader

Abstract

The invention discloses a traditional Chinese medicine composition, a traditional Chinese medicine preparation and application of the traditional Chinese medicine composition and the traditional Chinese medicine preparation, and relates to the technical field of medicine production. 5-30 parts of cassia twig; 1-10 parts of fish oil; 3-25 parts of Chinese angelica; 3-25 parts of ligusticum wallichii; 5-20 parts of peach kernels; 5-20 parts of codonopsis pilosula; 5-20 parts of fresh ginger; 5-30 parts of honey-fried licorice root; and 10 to 100 parts of gypsum. The traditional Chinese medicine composition disclosed by the invention has the characteristics of multiple targets, small toxic and side effects and the like, and plays a role in treating cerebral infarction mainly by improving hemorrheology, inhibiting thrombosis, enhancing organism immunity, inhibiting activation of microglial cells in the brain and injury of mature neurons, improving neuronal apoptosis and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medicine production, and in particular to a Chinese medicine composition, a Chinese medicine preparation and applications thereof. Background Art

[0002] Cerebral infarction (CI) is the main manifestation of ischemic stroke. It is caused by ischemic necrosis or softening of local brain tissue due to cerebral blood supply disorder, ischemia and hypoxia. Common clinical types of cerebral infarction include cerebral thrombosis, lacunar infarction and cerebral embolism. Cerebral infarction accounts for 80% of all strokes. The main clinical manifestations are sudden fainting, unconsciousness, hemiplegia, speech disorders and intellectual disabilities.

[0003] Western medicine has obvious advantages in treating acute stroke. Thrombolysis, antiplatelet aggregation, anticoagulation, brain metabolism promotion, brain nerve nutrition and other symptomatic treatments are often given clinically. Early thrombolytic therapy can significantly reduce sequelae and improve patient prognosis, but thrombolytic therapy has relatively strict indications and a short thrombolytic time window. Most patients cannot be sent to the hospital in time and miss the best time for thrombolysis. 70% of the surviving patients have varying degrees of disability, which has brought a heavy burden to their families and society.

[0004] In addition, although Western medicine is often used to treat cerebral infarction in clinical practice, it has serious side effects and poor effects, and cannot fundamentally solve the cause of the disease and prevent cerebral infarction. Summary of the invention

[0005] The main purpose of the present invention is to provide a Chinese medicine composition, a Chinese medicine preparation and its application, aiming to solve the problems that the existing Chinese and Western medicines have large side effects, poor therapeutic effects and cannot prevent cerebral infarction.

[0006] To achieve the above object, the present invention provides a Chinese medicine composition, comprising the following raw materials in parts by weight:

[0007] Ephedra 5-20 parts;

[0008] 5-30 parts of cinnamon twig;

[0009] 1-10 portions of fish oil;

[0010] 5-25 parts of Chinese Angelica;

[0011] 5-25 parts of Chuanxiong;

[0012] 5-20 portions of peach kernels;

[0013] 5-20 parts of Codonopsis pilosula;

[0014] 5-20 portions of ginger;

[0015] 5-30 parts of roasted liquorice root; and 10-100 parts of gypsum.

[0016] In one embodiment, the traditional Chinese medicine composition further comprises the following raw materials in parts by weight: 1 to 10 parts of aconite root and 5 to 15 parts of pinellia tuber.

[0017] In one embodiment, the Chinese medicine composition comprises the following raw materials in parts by weight: 5 to 15 parts of ephedra;

[0018] 5-15 parts of cinnamon twig;

[0019] 2-5 servings of fish oil;

[0020] 5-10 portions of Chinese Angelica;

[0021] 5-10 parts of Chuanxiong;

[0022] 5-15 servings of peach kernels;

[0023] 5-10 portions of Codonopsis pilosula;

[0024] 5-10 portions of ginger;

[0025] 5-15 parts of roasted liquorice root; and 20-50 parts of gypsum.

[0026] In one embodiment, the Chinese medicine composition comprises the following raw materials in parts by weight: 10 parts of ephedra;

[0027] 10 parts of cinnamon twig;

[0028] 5 portions of fish oil;

[0029] Angelica 9 parts;

[0030] 9 parts of Chuanxiong;

[0031] 10 portions of peach kernels;

[0032] 9 parts of Codonopsis pilosula;

[0033] 9 parts ginger;

[0034] 9 parts of roasted licorice root;

[0035] 30 parts of gypsum;

[0036] 9 parts of Aconite root; and

[0037] 9 servings of Pinellia ternata.

[0038] In one embodiment, the fish oil includes EPA and DHA, and the sum of the mass of EPA and DHA in the fish oil accounts for greater than or equal to 70%.

[0039] In one embodiment, the aconite type includes Heishunpian or Baifupian; and / or,

[0040] The peach kernels include processed stewed peach kernels; and / or,

[0041] The gypsum comprises raw gypsum; and / or,

[0042] The pinellia tuber includes Qing pinellia tuber or Fa pinellia tuber.

[0043] The present invention also provides a traditional Chinese medicine preparation, comprising the traditional Chinese medicine composition.

[0044] In one embodiment, the type of the traditional Chinese medicine preparation includes mixture, ointment, pill or capsule.

[0045] The present invention also provides an application of the above-mentioned Chinese medicine composition or Chinese medicine preparation in preparing an inhibitor of cerebral infarction.

[0046] In one embodiment, the cerebral infarction includes ischemic cerebral infarction.

[0047] The invention provides a Chinese medicine composition, a Chinese medicine preparation and an application thereof. The Chinese medicine composition is based on the compatibility principle of traditional Chinese medicine, with ephedra and cinnamon twig as the main ingredients, which can open the pores and dispel cold evil. The Chinese medicine composition can replenish fire and restore yang, dispel wind and cold, and dredge meridians when combined with aconite and ginger. The cinnamon twig can also regulate the nutrient and defensive qi and blood, warm yang and transform qi, and can warm the lungs and stop coughing, and treat phlegm and fluid when combined with ginger and peach kernel. The Chinese angelica and codonopsis are combined to replenish lung qi, nourish blood and activate blood circulation, and codonopsis and roasted licorice can replenish qi and strengthen the spleen and stomach. Spleen, promotes the production of body fluid and harmonizes the stomach, prevents sweating and damages the body; Gypsum is cold in nature, clears away heat and purges fire, restricts the warm nature of various medicines, prevents damage to the yin, and is used as a counter-assistant; fish oil and Chuanxiong promote blood circulation and dissipate blood stasis, and Chuanxiong can ascend to the head, lead various medicines to ascend to the top, and is compatible with Angelica and peach kernel, enhancing blood circulation and dissipating blood stasis, dispelling wind and unblocking collaterals to achieve the merit of "blood circulation and wind self-destruction"; Radix Glycyrrhizae Preparata can also be used to harmonize the middle and relieve urgency, reconcile various medicines, and play the effects of dispelling wind and strengthening the body, warming and unblocking the meridians, promoting qi and removing blood stasis, and protecting cerebral blood vessels. The Chinese medicine composition of the present invention has the characteristics of multiple targets and small toxic and side effects, and its treatment of cerebral infarction mainly plays a role by improving blood rheology, inhibiting thrombosis, enhancing body immunity, inhibiting the activation of microglia in the brain and the damage of mature neurons, and improving neuronal apoptosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the structures shown in these drawings without paying creative work.

[0049] Figure 1This is a graph showing the Zea Longa neurological symptom scoring results of the Chinese medicine compositions in Example 1, Example 2 and Comparative Example 1 provided by the present invention used in animal experiments;

[0050] Figure 2 This is a result diagram of cerebral infarction volume when the Chinese medicine compositions in Example 1, Example 2 and Comparative Example 1 provided by the present invention are used in animal experiments;

[0051] Figure 3 This is a graph showing the 2,3,5-triphenyltetrazolium chloride (TTC) staining results of the Chinese medicine compositions in Example 1, Example 2 and Comparative Example 1 provided by the present invention used in animal experiments;

[0052] Figure 4 This is a graph showing the brain water content results of the Chinese medicine compositions in Example 1, Example 2 and Comparative Example 1 provided by the present invention used in animal experiments;

[0053] Figure 5 This is a graph showing the results of activated partial thromboplastin time (APTT) when the Chinese medicine compositions in Example 1, Example 2 and Comparative Example 1 provided by the present invention are used in animal experiments;

[0054] Figure 6 This is a graph showing the prothrombin time (PT) results of the Chinese medicine compositions in Example 1, Example 2 and Comparative Example 1 provided by the present invention used in animal experiments;

[0055] Figure 7 The thrombin time (TT) result graph of the Chinese medicine composition in Example 1, Example 2 and Comparative Example 1 provided by the present invention used in animal experiments;

[0056] Figure 8 This is a fibrinogen (FIB) result diagram of the Chinese medicine composition in Example 1, Example 2 and Comparative Example 1 provided by the present invention used in animal experiments;

[0057] Fig. 9 This is a graph showing the results of using the Chinese medicine compositions in Example 1, Example 2 and Comparative Example 1 provided by the present invention for the anti-apoptotic factor Bcl-2 in animal experiments;

[0058] Fig.10 This is a graph showing the results of using the Chinese medicine compositions in Example 1, Example 2 and Comparative Example 1 provided by the present invention for the apoptosis-promoting factor Bax in animal experiments;

[0059] Fig.11 This is a graph showing the results of using the Chinese medicine composition in Example 1, Example 2 and Comparative Example 1 provided by the present invention for the apoptosis-promoting factor Caspase-3 in animal experiments;

[0060] Fig.12This is a graph showing the results of using the Chinese medicine composition in Example 1, Example 2 and Comparative Example 1 provided by the present invention for the apoptosis-promoting factor AIF in animal experiments;

[0061] Fig.13 This is a graph showing the NeuN results of neurons in the hippocampus of brain tissue in animal experiments using the Chinese medicine compositions in Example 1, Example 2 and Comparative Example 1 provided by the present invention.

[0062] The realization of the purpose, functional features and advantages of the present invention will be further explained in conjunction with embodiments and with reference to the accompanying drawings. DETAILED DESCRIPTION

[0063] To make the purpose, technical scheme and advantages of the embodiment of the present invention clearer, the technical scheme in the embodiment of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiment, it is carried out according to the normal conditions or the conditions recommended by the manufacturer. If the reagents or instruments used do not specify the manufacturer, they are all conventional products that can be purchased commercially. In addition, the meaning of "and / or" appearing in the full text includes three parallel schemes, taking "A and / or B" as an example, including scheme A, or scheme B, or schemes that A and B meet at the same time. In addition, the technical schemes between the various embodiments can be combined with each other, but must be based on the ability of ordinary technicians in the field to achieve. When the combination of technical solutions is contradictory or cannot be achieved, it should be considered that the combination of such technical solutions does not exist, and is not within the scope of protection required by the present invention. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in the field without making creative work belong to the scope of protection of the present invention.

[0064] Cerebral infarction (CI) is the main manifestation of ischemic stroke. It is caused by ischemic necrosis or softening of local brain tissue due to cerebral blood supply disorder, ischemia and hypoxia. Common clinical types of cerebral infarction include cerebral thrombosis, lacunar infarction and cerebral embolism. Cerebral infarction accounts for 80% of all strokes. The main clinical manifestations are sudden fainting, unconsciousness, hemiplegia, speech disorders and intellectual disabilities. Cerebral infarction, as a sudden brain disease, can occur at any age, and is more common in middle-aged and elderly people aged 45 to 70. The onset is acute, often without prodromal symptoms. Focal neurological signs reach a peak within minutes to hours, and often present as complete stroke with clear consciousness or mild disturbance of consciousness. Embolism of the internal carotid artery or middle cerebral artery trunk leads to large-area cerebral infarction, which may cause severe cerebral edema, increased intracranial pressure, and even brain herniation and coma, and rarely epileptic seizures. Embolism of the vertebral basilar artery system often causes coma. In some cases, focal signs are stable or improved for a period of time and then worsen, indicating recurrence of infarction or secondary bleeding.

[0065] Cerebral infarction belongs to the category of "stroke" in traditional Chinese medicine. Traditional Chinese medicine believes that the etiology and pathogenesis of ischemic stroke are complex, mainly including external deficiency, fire, wind, phlegm, qi, blood, etc., that is, it is closely related to internal injuries, irregular diet, obesity, excessive phlegm, qi deficiency and evil. The main causes are internal liver wind, insufficient blood supply to the cerebral blood vessels, stagnant blood flow, sequelae of stroke bleeding or falls, resulting in brain cell hypoxia and necrosis, meridian blockage, blocked blood vessels, depression, phlegm obscuring the clear orifices, blood stasis blocking the meridians, coma, dementia, paralysis, immobility of the limbs, loss of memory or cataracts, blindness, headache, dizziness or coma, vascular sclerosis, hyperplasia and calcification, plaque formation of small blood clots, leading to insufficient oxygen supply, hemiplegia, aphasia, difficulty eating and swallowing, impaired consciousness, etc. The internal artery can cause blindness in the ipsilateral eye, but because of vascular disease, it causes hemiplegia, movement disorders, memory loss, abnormal gait, bedridden, inability to take care of oneself, muscle atrophy, stiff and deformed joints, inversion of the foot, eversion of the foot, shaky walking, and inability to bend fingers and other sequelae.

[0066] In Western medical theory, coagulation function plays a key role in the pathogenesis of cerebral infarction. After the endothelium of the blood vessel wall is damaged, the formed elements in the blood are more likely to adhere and deposit, stimulating the release of more coagulation factors. In addition, the patient's abnormal glucose and lipid metabolism causes an increase in the levels of lipoproteins, cholesterol, fibrinogen, etc., which reduces the blood flow rate and improves the blood coagulation state. Therefore, for patients with cerebral infarction, improving the hypercoagulable state of the blood is of great significance to the patient's rehabilitation effect in terms of restoring cerebral blood perfusion, restoring cerebral blood oxygen supply, promoting the recovery of damaged nerve tissue, and reducing the complication rate.

[0067] At present, drugs used to improve the hypercoagulable state of blood include aspirin, and its therapeutic mechanism is to prevent platelet aggregation. However, 47% of aspirin users will develop drug resistance, and long-term use will cause adverse reactions such as gastrointestinal damage, liver and kidney damage, and impaired coagulation function. At the same time, aspirin can only have a certain relief effect after the onset of cerebral infarction and prevent recurrence. It has no benefit in the treatment and prevention of ischemic stroke, but significantly increases the risk of bleeding, and has no obvious repair effect on cerebral infarction tissue.

[0068] Therefore, although hemiplegia caused by cerebral infarction is currently mostly treated with Western medicine, Western medicine has great side effects, poor effects, and cannot fundamentally solve the cause of the disease and effectively prevent cerebral infarction.

[0069] In view of this, the present invention provides a Chinese medicine composition, comprising the following raw materials in parts by weight:

[0070] Ephedra 5-20 parts;

[0071] 5-30 parts of cinnamon twig;

[0072] 1-10 portions of fish oil;

[0073] 5-25 parts of Chinese Angelica;

[0074] 5-25 parts of Chuanxiong;

[0075] 5-20 portions of peach kernels;

[0076] 5-20 parts of Codonopsis pilosula;

[0077] 5-20 portions of ginger;

[0078] 5-30 parts of roasted licorice root; and

[0079] 10 to 100 parts of gypsum.

[0080] In the above formula, Ephedra is the herbaceous stem of Ephedra sinica Stapf, Ephedra equisetina Bunge or Ephedra intermedia Schrenk ex Mey. of the Ephedraceae family, which is pungent, slightly bitter, and warm in nature. It enters the lung and bladder meridians and has the effects of sweating, dispersing cold, clearing the lungs and relieving asthma, and promoting diuresis and reducing swelling.

[0081] Cinnamon twig: Cinnamomum cassia Presl or its dried young branches, pungent, sweet, warm in nature. It enters the heart, lung, and bladder meridians. It has the effects of sweating, relieving muscles, warming and unblocking meridians, assisting yang and transforming qi, and calming and descending qi.

[0082] Peach kernel: the dried mature seed of peach (Prunus persica) or wild peach (Prunus davidiana) of the Rosaceae family.

[0083] Angelica sinensis: It is the dried root of Angelica sinensis (Oliv.) Diels, a plant of the Umbelliferae family. It is sweet and spicy in taste and warm in nature. It enters the liver, heart and spleen meridians. It has the effects of nourishing blood, activating blood circulation, regulating menstruation and relieving pain, and moistening the intestines and relieving constipation.

[0084] Chuanxiong: It is the dried rhizome of the plant Chuanxiong (Ligusticum sinense'Chuanxiong') of the Umbelliferae family. It is pungent in taste and warm in nature. It enters the liver, gallbladder, and pericardium meridians. It has the effects of promoting blood circulation and qi, dispelling wind and relieving pain.

[0085] Codonopsis: It is a member of the Araliaceae family (Panax ginseng CAMey.), sweet, slightly bitter, and slightly warm in nature. It enters the spleen, lung, heart, and kidney meridians. It has the effects of greatly replenishing vital energy, restoring pulse and strengthening deficiency, replenishing spleen and lungs, promoting body fluid and nourishing blood, and calming the mind and improving intelligence.

[0086] Ginger: It is the dried rhizome of the ginger plant (Zingiber oj-jicinale Rosc.) of the ginger family. It is pungent and hot in nature. It enters the spleen, stomach, kidney, heart, and lung meridians. It has the effects of warming the middle and dispersing cold, restoring yang and unblocking meridians, and warming the lungs and eliminating phlegm.

[0087] Roasted Licorice: It is the product of licorice (Glycyrrhiza uralensis Fisch.) of the Leguminosae family roasted with honey. It is sweet and neutral in nature. It enters the heart, lung, spleen, and stomach meridians. It has the effects of tonifying the spleen and stomach, and replenishing qi and restoring the pulse.

[0088] Gypsum: Its scientific name is Gypsum Fibrosum. It is a kind of gypsum belonging to the anhydrite family of sulfate minerals. It tastes sweet and spicy and is very cold in nature. It enters the lung and stomach meridians. It has the effects of clearing away heat and purging fire, relieving restlessness and quenching thirst.

[0089] Fish oil: It is oil extracted from different kinds of fish, especially from fish rich in Omega-3 fatty acids. It is sweet and warm in nature. It has the effects of promoting blood circulation and reducing fat.

[0090] In the technical scheme of the present invention, the Chinese medicine composition is based on the compatibility principle of traditional Chinese medicine, with ephedra and cinnamon twig as the main ingredients, which can open the pores and dispel cold evil. The combination of aconite and ginger has the functions of replenishing fire and restoring yang, dispersing wind and cold, and dredging meridians; cinnamon twig can also harmonize the nutrient and defensive qi and blood, warm the yang and transform qi, and the combination of ginger and peach kernel has the effects of warming the lungs and relieving cough, and treating phlegm and fluid; angelica and codonopsis are combined to replenish lung qi, nourish blood and promote blood circulation, and codonopsis and roasted licorice can replenish qi and strengthen the spleen, and promote the production of body fluids. The Chinese medicine composition of the present invention has the characteristics of multiple targets and small toxic and side effects. It mainly treats cerebral infarction by improving blood rheology, inhibiting thrombosis, reducing blood lipids, enhancing immunity, inhibiting the activation of microglia in the brain, and improving neuronal apoptosis.

[0091] In some embodiments of the present invention, the Chinese medicine composition further comprises the following raw materials in parts by weight: 1 to 10 parts of aconite root and 5 to 15 parts of pinellia tuber.

[0092] Aconite: It is a processed product of the root of Aconitum carmichaelii Debx, a plant of the Ranunculaceae family. It is pungent, sweet, hot in nature, and toxic. It enters the heart, kidney, and spleen meridians. It has the effects of restoring yang, tonifying fire and boosting yang, and dispelling cold and relieving pain.

[0093] Pinellia: It is the tuber of Pinellia ternata (Thunb.) Breit., a plant of the Araceae family. It has the effects of drying dampness and resolving phlegm, relieving adverse symptoms and stopping vomiting, and eliminating lumps and dispersing nodules.

[0094] In the technical scheme of the present invention, the aconite can regulate the Yingwei Qi and blood, warm the Yang and transform the Qi, and can be used with ginger, pinellia tuber and peach kernel to warm the lungs and relieve cough, and treat phlegm and fluid. The aconite is preferably processed aconite slices.

[0095] In some embodiments of the present invention, the Chinese medicine composition comprises the following raw materials in parts by weight:

[0096] 5-15 parts of Ephedra;

[0097] 5-15 parts of cinnamon twig;

[0098] 2-5 servings of fish oil;

[0099] 5-10 portions of Chinese Angelica;

[0100] 5-10 parts of Chuanxiong;

[0101] 5-15 servings of peach kernels;

[0102] 5-10 portions of Codonopsis pilosula;

[0103] 5-10 portions of ginger;

[0104] 5-15 parts of roasted licorice root; and

[0105] 20 to 50 parts of gypsum.

[0106] Under this formula, the effect of treating cerebral infarction is better.

[0107] In some embodiments of the present invention, the Chinese medicine composition comprises the following raw materials in parts by weight:

[0108] Ephedra 10 parts;

[0109] 10 parts of cinnamon twig;

[0110] 5 portions of fish oil;

[0111] Angelica 9 parts;

[0112] 9 parts of Chuanxiong;

[0113] 10 portions of peach kernels;

[0114] 9 parts of Codonopsis pilosula;

[0115] 9 parts ginger;

[0116] 9 parts of roasted licorice root;

[0117] 30 parts of gypsum;

[0118] 9 parts of Aconite root; and

[0119] 9 servings of Pinellia ternata.

[0120] Among them, ephedra and cinnamon twig are the main medicines, fish oil, Chuanxiong, angelica, aconite, etc. are the auxiliary medicines, peach kernel, Codonopsis pilosula, ginger, licorice, gypsum, Pinellia, etc. are the left-helper medicines. This formula is most effective in preventing and treating cerebral infarction.

[0121] In some embodiments of the present invention, the fish oil includes EPA and DHA, and the sum of the mass of EPA and DHA in the fish oil accounts for greater than or equal to 70%. Omega-3 unsaturated fatty acids in fish oil, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have good application prospects in the prevention and treatment of various cardiovascular diseases. In the technical scheme of the present invention, EPA may be used as a 3-series prostaglandin (PG) precursor to generate active substances such as PG inhibitor (PGI3) and thromboxane A3 (TXA3) under the action of lipid / cyclooxygenase, thereby inhibiting platelet aggregation and prolonging bleeding time. At the same time, DHA may participate in brain function to achieve the prevention and treatment of cerebral infarction.

[0122] In some embodiments of the present invention, the aconite type includes Heishunpian or Baifupian.

[0123] Among them, Heishunpian is one of the products obtained after special processing of aconite. Usually, other auxiliary materials such as vinegar, wine, licorice, black beans, etc. are added during the processing to make its color black or dark brown. Heishunpian has a stronger medicinal effect. Baifupian is another common aconite processing product. Its processing process removes more impurities and toxic components, and its color is lighter, close to white or light yellow. Baifupian is more processed, has a weaker toxicity, and is easy to decoct.

[0124] In some embodiments of the present invention, the peach kernel includes a processed product, stewed peach kernel. Stewed peach kernel is a processed form of peach kernel of traditional Chinese medicine, and the stewed peach kernel is easier to digest and absorb. Stewed peach kernel is often used for promoting blood circulation and removing blood stasis, moistening the intestines and relieving constipation, etc.

[0125] In some embodiments of the present invention, the gypsum includes raw gypsum. Compared with other processed products, such as calcined gypsum (the main component of which is anhydrous calcium sulfate), the main component of raw gypsum is dihydrate calcium sulfate, which has the effects of enhancing heat-clearing and detoxifying, promoting body fluid and quenching thirst, and is more suitable for the symptoms of cerebral infarction.

[0126] In some embodiments of the present invention, the pinellia tuber includes clear pinellia tuber or French pinellia tuber. Clear pinellia tuber is made by washing freshly collected pinellia tuber tuber and directly soaking it in clean water and changing the water several times until its taste becomes lighter; French pinellia tuber is pinellia tuber processed by a specific processing method, usually including processing with auxiliary materials such as lime water or licorice.

[0127] The present invention also provides a traditional Chinese medicine preparation, comprising the traditional Chinese medicine composition.

[0128] The Chinese medicine preparation includes all the technical solutions of the pharmaceutical composition, and therefore also has all the beneficial effects brought by the above solutions, which will not be described one by one here.

[0129] In some embodiments of the present invention, the type of the Chinese medicine preparation includes a mixture, an ointment, a pill or a capsule. The type of the Chinese medicine preparation can be changed according to the specific usage scenario to achieve the best therapeutic effect.

[0130] The present invention also provides an application of the above-mentioned Chinese medicine composition or Chinese medicine preparation in preparing an inhibitor of cerebral infarction.

[0131] The application includes all technical solutions of the pharmaceutical composition, and therefore also has all the beneficial effects brought by the above solutions, which will not be described one by one here.

[0132] In some embodiments of the present invention, the cerebral infarction includes ischemic cerebral infarction. The Chinese medicine composition or Chinese medicine preparation of the present invention can significantly improve and reduce the cerebral infarction volume and brain water content of the model animal, improve brain edema and coagulation function, thereby regulating the phenomenon of poor blood circulation and repairing necrotic brain tissue, and can therefore be used to prevent and treat ischemic cerebral infarction, i.e., ischemic stroke.

[0133] The technical solution of the present invention is further described in detail below in conjunction with specific embodiments and drawings. It should be understood that the following embodiments are only used to explain the present invention and are not used to limit the present invention.

[0134] Example 1

[0135] A Chinese medicine composition comprising:

[0136] Ephedra 10g, cinnamon twig 10g, fish oil 2g, peach kernel 10g, roasted licorice root 6g, angelica 9g, Chuanxiong 9g, Codonopsis pilosula 9g, ginger 9g, gypsum 10g.

[0137] Example 2

[0138] A Chinese medicine composition comprising:

[0139] Ephedra 10g, cinnamon twig 10g, fish oil 5g, peach kernel 10g, roasted licorice root 9g, angelica 9g, Chuanxiong 9g, Codonopsis pilosula 9g, ginger 9g, aconite 9g, gypsum 20g, Pinellia 9g.

[0140] Comparative Example 1

[0141] A Chinese medicine composition comprising:

[0142] Ephedra 10g, cinnamon twig 10g, peach kernel 10g, roasted licorice root 6g, angelica 3g, Chuanxiong 3g, gypsum 5g.

[0143] Performance Testing

[0144] Preparation of Chinese medicine composition: Ephedra, cinnamon twig, angelica, chuanxiong, peach kernel, codonopsis, ginger, licorice, gypsum, aconite, and pinellia in Examples 1-2 and Comparative Example 1 are weighed in corresponding proportions, and 8 times the weight of water is added, soaked for 30-40 minutes, boiled over high heat, decocted over low heat for 30 minutes, filtered through a 200-mesh filter, and decocted twice, the method is the same as above. The twice-decocted medicinal liquid is concentrated into an extract, and fish oil is added in corresponding proportions, and stirred evenly to obtain 3 groups of Chinese medicine compositions.

[0145] Drug group: The three groups of Chinese medicine compositions prepared above were respectively taken and prepared into a drug solution with a concentration of 1 g / mL with pure water.

[0146] Animal grouping, modeling and drug administration:

[0147] 1. Adaptation period: 100 SPF male SD rats, 6-7 weeks old, weighing (250±20) g, were provided by Hunan Slake Jingda Experimental Animal Co., Ltd. The experimental animal production license number is SCXK (Xiang) 2019-0004 (valid until June 5, 2024), issued by the Hunan Provincial Department of Science and Technology. The experimental rats were observed for 7 days during the adaptation period, and the formal experimental period began after no abnormalities were found.

[0148] 2. Modeling period and grouping: Middle cerebral artery occlusion (MCAO) is currently the most commonly used model of focal cerebral ischemia (ischemic stroke / cerebral infarction). The MCAO model first blocks the external carotid artery (ECA) and its branches, and blocks the pterygopalatine artery (PPA) to cut off the collateral blood flow from the extracranial source. A nylon thread is inserted from the ECA, through the internal carotid artery (ICA) to the anterior cerebral artery (ACA), and the blood supply at the origin of the middle cerebral artery (MCA) is mechanically blocked to establish the middle cerebral artery ischemia model. In this model, the nylon thread can be pulled out without anesthesia, blood flow can be restored, and reperfusion can be achieved. The thread occlusion method has the advantages of no craniotomy, definite effect, and accurate control of ischemia and reperfusion time. It is ideal for studying the sensitivity and tolerance of neurons to ischemia, drug efficacy observation, reperfusion damage and treatment time window. It also has the characteristics of little impact on the whole body and long animal survival time, which is suitable for the study of chronic brain injury. Controlling variable factors can avoid the instability of experimental results.

[0149] 15 cases were randomly selected as sham operation group, and the remaining 85 cases were used for MCAO modeling. Fish line was inserted into the ICA artery. After the model was prepared, the score was scored according to Zea Longa's 5-point method. The animals with the first score of 1-3 points were considered to be successfully modeled. At least 60 model animals were selected and then divided into model group, comparative example 1, embodiment 2, and embodiment 3, with at least 15 animals in each group.

[0150] Table 1 Zea Longa neurological symptom score table

[0151] Points Neurological symptoms 0 No neurological deficits 1 Mild focal neurological deficit, i.e., inability to extend the left forepaw with the tail lifted 2 Moderate focal neurological deficit, walking and turning to the left 3 Moderate focal neurological deficits, i.e. difficulty walking, leaning to the left side

[0152] 3. Drug administration: After modeling and grouping, each group of animals was gavaged with drug administration at a volume of 10 mL / kg, once a day for 14 consecutive days. The blank group and model control group were given an equal volume of pure water, and the drug group was administered according to the set dose.

[0153] 4. Index determination and final treatment: Zea Longa scores were performed before and on the 14th day of administration. After the neurological symptom scoring was completed on the 14th day of administration, the animals were euthanized by blood drawing from the abdominal aorta after anesthesia. After blood collection, the serum was separated and divided into two parts, one for the determination of four coagulation items, namely prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen (FIB); the other was stored at -80°C for subsequent testing. After the last treatment, brain tissues of 7 animals in each group were taken for the determination of cerebral infarction volume percentage and brain water content percentage; the remaining brain tissues of the animals in each group were homogenized and used to detect the expression levels of apoptosis-related factors Bcl-2, Bax, Caspase-3, AIF and NeuN protein.

[0154] Method for determining the percentage of cerebral infarction volume: Place the rat brain tissue in a glass dish and cut it into 5 slices with a blade, with one slice cut every 2 mm. The first cut is made at the midpoint of the line connecting the anterior pole of the brain and the optic chiasm, the second cut is made at the optic chiasm, the third cut is made at the infundibulum handle, and the fourth cut is made between the infundibulum handle and the caudal pole of the posterior lobe; Place the brain slice in a glass dish containing 1% TTC solution, cover it with tin foil to avoid light, and place it in a 37°C constant temperature incubator to avoid light for 20 minutes. Turn the brain slice once every 10 minutes. Turn it carefully and gently to make it evenly contact with the staining solution; After TTC staining, place the brain slice in 10% formaldehyde solution to avoid light and fix it for 24 hours, then take it out and take a picture; Use Image J image analysis software to analyze the cerebral infarction area, the normal part is red, the infarction part is white, and the cerebral infarction volume is calculated according to the volume calculation formula. In order to reduce the influence of brain swelling and individual differences on the experimental results, the results are expressed as cerebral infarction volume ratio; Calculate and count according to the following formula:

[0155] Infarct volume: V = (A1 + A2 + ... + An) t / 2

[0156] Note: t is the slice thickness, A1 and A2 represent the infarct area at the nasal and caudal sides of the slice, respectively. Infarct volume ratio % = infarct volume / ipsilateral cerebral hemisphere volume × 100%

[0157] Method for determining the percentage of brain water content: weigh the brain immediately after taking it, which is the wet weight of the brain. After TTC staining, put the brain slices into a glass dish lined with tin foil and dry them in an oven to a constant weight, which is the brain stem weight. Calculate and count according to the following formula:

[0158] Brain water content% = (brain wet weight - brain stem weight) / brain wet weight × 100%

[0159] 5. Data processing: The data were processed by ECGAUTO software and then analyzed by SPSS17.0 statistical software. The measured data of each group were expressed as x-±sem, and the Student-T test (paired T test) was used to compare the statistics of each experimental group with those before administration. Before the inter-group comparison of each experimental group, an inter-group variance analysis (F-test) was performed first. When the inter-group variances were equal, the inter-group comparison was performed by the Student-T test (unpaired T test). When the inter-group variances were unequal, the corrected Student-T test was used for statistical analysis.

[0160] Experimental Results

[0161] 1. Zea Longa neurological function scores of rats in each group before and after treatment

[0162] Depend on Figure 1 It can be seen that compared with the blank group, the Zea Longa score of the model group was significantly increased (P<0.01), and there was no significant change before and after treatment (P>0.05), indicating that the MCAO rat model was successful and the disease model was stable. After 14 days of drug treatment, the results showed that: Comparative Example 1, Example 1 and Example 2 were significantly different from the model group (P<0.05), and the neurobehavior of MCAO rats could be significantly improved, among which Example 2 had the most significant statistical difference, which preliminarily showed that Example 1 and Example 2 had a good therapeutic effect on rats with cerebral infarction.

[0163] Figure 1 In the table, ** indicates a very significant difference compared with the blank group (P<0.01); # indicates a significant difference compared with the model group (P<0.05); ## indicates a very significant difference compared with the model group (P<0.01).

[0164] 2. Results of cerebral infarction volume in rats of each group

[0165] like Figure 2 and Figure 3As shown: TTC staining revealed that the TTC staining of the brain tissue of the blank group rats was normal, without abnormal necrosis; the left brain tissue of the model group rats was severely necrotized, and the brain tissue infarction area was large (white area); there was no significant difference between the comparative example 1 and the model group, indicating that it had no obvious therapeutic effect on the treatment of cerebral infarction. Both Example 1 and Example 2 had a certain therapeutic effect on rats with cerebral infarction, among which Example 2 had the most significant therapeutic effect, and the TTC-stained infarction area was significantly reduced, which could effectively improve the necrosis of rat brain tissue and had a good protective effect on brain tissue. It shows that the prescription and compatibility of Example 2 are scientific and effective, and the therapeutic effect is significant.

[0166] Figure 2 In the table, ** indicates a very significant difference compared with the blank group (P<0.01); # indicates a significant difference compared with the model group (P<0.05); ## indicates a very significant difference compared with the model group (P<0.01).

[0167] 3. Water content of brain tissue of rats in each group

[0168] The water content of brain tissue of rats in different groups was measured. Figure 4 As shown in the figure: after modeling, it was found that the water content of the rats in the model group was significantly increased (P<0.01), and brain edema occurred, indicating that the brain tissue of the rats in the model group showed pathological damage. After treatment with the Chinese medicine composition, the brain water content showed a downward trend, indicating that after drug treatment, the brain edema state of rats with cerebral infarction was alleviated to a certain extent; among them, compared with the model group, Example 1 and Example 2 had significant differences, and the statistical difference of Example 2 was the most obvious, indicating that it has a good therapeutic effect on brain edema caused by cerebral infarction and has a certain protective effect on brain tissue.

[0169] Figure 4 In the table, ** indicates a very significant difference compared with the blank group (P<0.01); # indicates a significant difference compared with the model group (P<0.05); ## indicates a very significant difference compared with the model group (P<0.01).

[0170] 4. Four coagulation tests of rats in each group

[0171] The blood coagulation test results of different groups of rats were as follows: Figure 5 , Figure 6 , Figure 7 and Figure 8As shown: compared with the blank group, the PT, APTT and TT levels in the blood of the model group were significantly decreased, and the FIB content was significantly increased, indicating that MCAO rats had coagulation and thrombosis, resulting in obstruction of cerebral blood flow and cerebral ischemia; after treatment with the Chinese medicine group, the coagulation indexes were improved to varying degrees, indicating that Chinese medicine has a good regulatory effect on the poor blood circulation caused by cerebral infarction; compared with the model group, the PT, APTT and TT levels in Example 1 and Example 2 were significantly increased, and the FIB content was significantly decreased, which can effectively treat coagulation and thrombosis after cerebral infarction, regulate the blood circulation of the heart and brain, and thus play the effects of promoting blood circulation, removing blood stasis, and promoting qi and nourishing blood.

[0172] Figures 5 to 8 In the table, ** indicates a very significant difference compared with the blank group (P<0.01); # indicates a significant difference compared with the model group (P<0.05); ## indicates a very significant difference compared with the model group (P<0.01).

[0173] 5. Expression of cell necrosis and apoptosis-related factors in brain tissues of each group

[0174] The contents of cell necrosis and apoptosis-related factors in the brain tissues of rats in different groups were detected. Fig. 9 , Fig.10 , Fig.11 and Fig.12 As shown in the results: compared with the blank group, the anti-apoptotic factor Bcl-2 in the model group was significantly decreased, and the pro-apoptotic factors Bax, Caspase-3, and AIF were significantly increased, indicating that the apoptosis of brain tissue cells in rats with cerebral infarction was aggravated, the degree of cerebral infarction was deepened, and the infarcted tissue could not be repaired normally. After treatment with the Chinese medicine group, the comparative example 1 had a trend of regulating the expression of apoptosis-related factors Bcl-2, Bax, Caspase-3, and AIF. Examples 1 and 2 could significantly increase Bcl-2 and reduce the contents of Bax, Caspase-3, and AIF. Among them, the effect of Example 2 was the most significant, indicating that it could effectively inhibit the apoptosis and necrosis process of brain tissue cells, promote the repair of necrotic brain tissue, have a good repair effect on the necrotic brain tissue of rats with cerebral infarction, and effectively protect the tissue.

[0175] Figures 9 to 12 In the table, ** indicates a very significant difference compared with the blank group (P<0.01); # indicates a significant difference compared with the model group (P<0.05); ## indicates a very significant difference compared with the model group (P<0.01).

[0176] 6. NeuN expression in the hippocampus neurons of the brain tissue of rats in each group

[0177] Cerebral infarction is accompanied by brain tissue death and focal neuronal damage. Neuronal nucleus (NeuN) is a neuron-specific nuclear protein that is mainly expressed in mature neurons and can be used as a reliable marker for mature neurons. Based on the above research, we further examined the effects of drugs on neuronal cells by immunohistochemical determination of NeuN expression. The results are as follows Fig.13 As shown: compared with the blank group, the expression level of NeuN in the hippocampus of the rats in the model group was significantly reduced, indicating that the rats with cerebral infarction had significant neuronal necrosis or nerve damage; compared with the model group, the comparative example 1 had a trend of increasing the expression level of NeuN, but there was no statistical difference, the expression level of NeuN in Examples 1 and 2 was significantly increased, among which the effect of Example 2 was the most obvious, indicating that it can effectively restore neuronal damage in the brain, repair necrotic nerve cells and brain tissue, thereby effectively alleviating the symptoms of cerebral infarction.

[0178] Fig.13 In the table, ** indicates a very significant difference compared with the blank group (P<0.01); # indicates a significant difference compared with the model group (P<0.05); ## indicates a very significant difference compared with the model group (P<0.01).

[0179] In summary, the Chinese medicine composition provided by the present invention has a good therapeutic effect on the rat cerebral infarction (ischemic cerebral infarction) model caused by the MCAO method: (1) in neurobehavior: it significantly reduced the pathological behavior score of the model rats, improved the physiological state of the rats, and had a good therapeutic effect; (2) TTC staining: it significantly reduced the cerebral infarction volume of the model rats, significantly reduced the brain water content of the model rats, and improved the brain edema of the model rats; (3) it significantly improved the coagulation index, indicating that the Chinese medicine composition of the present invention has a good regulatory effect on the poor blood circulation caused by cerebral infarction; (4) The Chinese medicine composition of the present invention can regulate the expression of apoptosis factors Bcl-2, Bax, Caspase-3, and AIF, has a good repair effect on the necrotic brain tissue of rats with cerebral infarction, and can effectively protect the tissue; (5) The Chinese medicine composition of the present invention can effectively restore the damage of neurons in the brain, repair necrotic nerve cells and brain tissue, and further improve nerve function, thereby effectively alleviating the symptoms of cerebral infarction.

[0180] The above are only preferred embodiments of the present invention, and do not limit the patent scope of the present invention. For those skilled in the art, the present invention may have various changes and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the patent protection scope of the present invention.

Claims

1. A Chinese medicine composition, characterized in that: The invention comprises the following raw materials in parts by weight: Ephedra 5-20 parts; 5-30 parts of cinnamon twig; 1-10 portions of fish oil; 5-25 parts of Chinese Angelica; 5-25 parts of Chuanxiong; 5-20 portions of peach kernels; 5-20 parts of Codonopsis pilosula; 5-20 portions of ginger; 5-30 parts of roasted licorice root; and 10 to 100 parts of gypsum.

2. The Chinese medicine composition according to claim 1, characterized in that The Chinese medicine composition also includes the following raw materials in parts by weight: 1 to 10 portions of Aconite and 5 to 15 portions of Pinellia.

3. The Chinese medicine composition according to claim 1, characterized in that: The Chinese medicine composition comprises the following raw materials in parts by weight: 5-15 parts of Ephedra; 5-15 parts of cinnamon twig; 2-5 servings of fish oil; 5-10 portions of Chinese Angelica; 5-10 parts of Chuanxiong; 5-15 servings of peach kernels; 5-10 portions of Codonopsis pilosula; 5-10 portions of ginger; 5-15 parts of roasted licorice root; and 20 to 50 parts of gypsum.

4. The Chinese medicine composition according to claim 2, characterized in that: The Chinese medicine composition comprises the following raw materials in parts by weight: Ephedra 10 parts; 10 parts of cinnamon twig; 5 portions of fish oil; Angelica sinensis 9 parts; 9 parts of Chuanxiong; 10 portions of peach kernels; 9 parts of Codonopsis pilosula; 9 parts ginger; 9 parts of roasted licorice root; 30 parts of gypsum; 9 parts of Aconite root; and 9 servings of Pinellia ternata.

5. The Chinese medicine composition according to claim 1, characterized in that: The fish oil includes EPA and DHA, and the sum of the mass of EPA and DHA in the fish oil accounts for greater than or equal to 70%.

6. The Chinese medicine composition according to claim 2, characterized in that: The type of aconite includes Heishunpian or Baifupian; and / or, The peach kernels include processed stewed peach kernels; and / or, The gypsum comprises raw gypsum; and / or, The pinellia tuber includes Qing pinellia tuber or Fa pinellia tuber.

7. A Chinese medicine preparation, characterized in that: Comprising the Chinese medicine composition as described in any one of claims 1 to 6.

8. The Chinese medicine preparation according to claim 7, characterized in that: The types of the Chinese medicine preparations include mixtures, ointments, pills or capsules.

9. Use of the Chinese medicine composition according to any one of claims 1 to 6 or the Chinese medicine preparation according to any one of claims 7 to 8 in the preparation of an inhibitor of cerebral infarction.

10. The use according to claim 9, characterized in that The cerebral infarction includes ischemic cerebral infarction.

Citation Information

Patent Citations

  • Traditional Chinese medicine formula for qi tonifying and blood circulation promoting

    CN107596284A

  • Decoction for treatment of stroke

    CN109481641A